Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy

Aron Goldhirsch; Urs Leuenberger; Hans Jörg Ryssel; Franco Cavalli; Roland W. Sonntag; Rudolph A. Joss; Kurt W. Brunner

doi:10.1159/000225652

Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy

Aron Goldhirsch, Urs Leuenberger, Hans Jörg Ryssel, Franco Cavalli, Roland W. Sonntag, Rudolph A. Joss, Kurt W. Brunner

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27%) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50%) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18% for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.

Original language	English (US)
Pages (from-to)	284-286
Number of pages	3
Journal	Oncology (Switzerland)
Volume	39
Issue number	5
DOIs	https://doi.org/10.1159/000225652
State	Published - 1982

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000225652

Cite this

@article{98e1f9edb831433eb5e6783a1d4ed4f0,

title = "Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy",

abstract = "33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27%) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50%) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18% for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.",

author = "Aron Goldhirsch and Urs Leuenberger and Ryssel, {Hans J{\"o}rg} and Franco Cavalli and Sonntag, {Roland W.} and Joss, {Rudolph A.} and Brunner, {Kurt W.}",

year = "1982",

doi = "10.1159/000225652",

language = "English (US)",

volume = "39",

pages = "284--286",

journal = "Oncology (Switzerland)",

issn = "0030-2414",

publisher = "S. Karger AG",

number = "5",

}

TY - JOUR

T1 - Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy

AU - Goldhirsch, Aron

AU - Leuenberger, Urs

AU - Ryssel, Hans Jörg

AU - Cavalli, Franco

AU - Sonntag, Roland W.

AU - Joss, Rudolph A.

AU - Brunner, Kurt W.

PY - 1982

Y1 - 1982

N2 - 33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27%) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50%) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18% for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.

AB - 33 patients were treated with a combination of tamoxifen and fluoxymesterone (10 mg t.i.d. each) after progression on prior hormonotherapy (HT). 6 of 22 patients (27%) exhibiting a partial response (PR) or stable disease (NC) on previous HT responded to the combination (median time to relapse 7 months, range 3.5 to 17+ months). 11 (50%) maintained NC (median duration 5 months, range 2+ to 9.5 months). No response has been seen in 11 patients who experienced progressive disease during prior hormonal manipulation or who were not evaluable for response to prior HT. The overall response rate was 18% for the patient population as a whole (responders and nonresponders to previous HT), which most probably would be similar to the response rate if these patients received only fluoxymesterone.

UR - http://www.scopus.com/inward/record.url?scp=0019986774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019986774&partnerID=8YFLogxK

U2 - 10.1159/000225652

DO - 10.1159/000225652

M3 - Article

C2 - 7048171

AN - SCOPUS:0019986774

SN - 0030-2414

VL - 39

SP - 284

EP - 286

JO - Oncology (Switzerland)

JF - Oncology (Switzerland)

IS - 5

ER -

Combination hormonotherapy with tamoxifen and fluoxymesterone in patients with advanced breast cancer relapsing on hormonotherapy

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this